Taro Pharm Inds (TARO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2024 | 03-2023 | 03-2022 | 03-2021 | 03-2020 | |
| Sales | 629,182 | 572,952 | 561,347 | 548,970 | 644,769 |
| Cost of Goods | 324,226 | 304,629 | 268,225 | 252,314 | 245,044 |
| Gross Profit | 304,956 | 268,323 | 293,122 | 296,656 | 399,725 |
| Operating Expenses | 283,697 | 251,238 | 229,888 | 710,745 | 153,234 |
| Operating Income | 21,485 | 17,714 | 63,459 | -413,775 | 246,535 |
| Other Income | 61,183 | 20,499 | 14,399 | 22,702 | 51,500 |
| Pre-tax Income | 82,668 | 38,213 | 77,858 | -391,073 | 298,035 |
| Income Tax | 28,801 | 12,768 | 19,592 | 9,667 | 53,485 |
| Net Income Continuous | 53,867 | 25,445 | 58,266 | -400,740 | 244,550 |
| Minority Interests | N/A | N/A | N/A | -14,087 | 309 |
| Net Income | $53,867 | $25,445 | $58,266 | $-386,653 | $244,241 |
| EPS Basic Total Ops | 1.43 | 0.68 | 1.55 | -10.12 | 6.35 |
| EPS Basic Continuous Ops | 1.43 | 0.68 | 1.55 | -10.49 | 6.36 |
| EPS Diluted Total Ops | 1.43 | 0.68 | 1.55 | -10.12 | 6.35 |
| EPS Diluted Continuous Ops | 1.43 | 0.68 | 1.55 | -10.49 | 6.36 |
| EPS Diluted Before Non-Recurring Items | 1.77 | 0.68 | 3.36 | 3.70 | 6.35 |
| EBITDA(a) | $44,746 | $58,013 | $102,713 | $-390,095 | $267,918 |